This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.
We care about your feedback. Let us know how we can improve your CancerCompass experience.